

March 24 - 26, 2020 | San Francisco, CA
www.autoimmune-modeling.com

**BOOK EARLY
AND SAVE
\$500**

PREDiCT: AUTOIMMUNE DISEASE MODELING SUMMIT

**Deploy Advanced Models to
Enhance Your Confidence &
Understanding of Molecular
Biological Pathway & Efficacy**

Expert Speakers Include:



Anish Suri
Chief Scientific
Officer
Cue Biopharma



David Fox
Professor of
Rheumatology and
Professor of Internal
Medicine
**University of
Michigan**



Hella Kohlhof
Chief Scientific
Officer
Immunix AG



Jason DeVoss
Principal Scientist
Amgen Inc.



Changyun Hu
Senior Scientist
**Jounce
Therapeutics**

Great conference. I came away feeling that I knew everyone there by the end on some level and had a lot of great discussions. I also gained additional perspective from this meeting!

Terry Van Vleet, Head of Mol & Comp Toxicology, AbbVie, Past PREDiCT Attendee

Welcome to the **PREDiCT: Autoimmune Disease Modeling Summit**

Validating effective novel targets is key during autoimmune therapeutic drug development. Over the last few years, we have seen breakthroughs in more advanced model utilization to validate novel target and biologic pathways, enabling faster preclinical-clinical drug development.

The inaugural **PREDiCT: Autoimmune Disease Modeling Summit** will unite the autoimmune research community to delve into the core challenges.

With the latest case studies from the likes of **Autoimmune Centers for Excellence, Immunic AG, Allergan, Cue Biopharma** and more, this 3-day summit will provide you with validated mechanisms to improve your preclinical and clinical outcomes and accelerate your autoimmune pipeline.

This is the definitive modeling meeting for autoimmune drug developers and leading researchers to share, discuss and collaborate. You will hear and learn from **industry leaders** on how to translate research model studies into real world applications, enhancing your confidence of target validation, safety profiling and efficacy.

We look forward to welcoming you in San Francisco in March!

Hear what PREDiCT past attendees have to say


“The meeting was excellent, well organized, with lots of relevant experts in one room - a fantastic networking opportunity”

Tomasz Kostrzewski,
Associate Director, Biology,
CN Bio Innovations


“The quality of the talks and the willingness to share insights amongst this elite crowd makes this meeting extremely valuable”

Doug Hinerfeld, Principal
Product Application Scientist,
Nanostring Technologies


Novel Therapeutic Targets Revealed By Industry Leaders



Autoimmune Center of Excellence reveal their latest research on new targets for CD6 and CD13 which can open doors to innovative autoimmune treatments.



Amgen unveil the potential for improving validation of *in vivo* autoimmune disease model through better identification and characterization of a novel human-relevant gene.



Immunic AG demonstrate how they utilize a novel orally available small molecule inhibitor to support autoimmune disease pipeline development.



Jounce Therapeutics address how they use B cells model to support preclinical and clinical decisions for type 1 diabetes preclinical study, and successfully translate into clinic.



Merck dissects what are key preclinical considerations to develop combination therapy in autoimmune diseases of RA and IBD, and how to uncover multiple indications of your potential candidate.

YOUR EXPERT SPEAKERS



Jason DeVoss
Principal Scientist
Amgen Inc.



Hella Kohlhof
Chief Scientific
Officer
Immunic AG



Changyun Hu
Senior Scientist
**Jounce
Therapeutics**



Anish Suri
Chief Scientific
Officer
Cue Biopharma



Zuoming Sun
Professor
**City of Hope
Medical Center**



Sunhwa Kim
Principal Scientist
Merck & Co



Josef Buttigieg
Associate Professor
**University of
Regina**



Marije Koenders
Assistant Professor
**Radboud Institute
for Molecular Life
Sciences (RIMLS)**



David Fox
Professor of
Rheumatology &
Professor of Internal
Medicine
**University of
Michigan**



Stephen Miller
Professor -
Microbiology-
Immunology,
**Northwestern
University**



Petr Ilyinski
Senior Director
**Selecta
Biosciences Inc.**



**Jessica Kenison-
White**
Senior Scientist
AnToIRx Inc



**Roland
Grenningloh**
Senior Director
- Immunology
Neurology
EMD Serono



**Michael
Mingueneau**
Associate Director,
Multiple Sclerosis &
NeuroInflammation
Research
Biogen



**Siddharth
Sukumaran**
Senior Scientist
Genentech



Alexis Scherl
Scientist, Research
Pathology
Genentech

It was very informative and useful to know the trends in immunotherapy modeling

**Padmini Jayaraman, Laboratory Director,
Baylor College of Medicine, Past PREDiCT
Attendee**

CONFERENCE DAY ONE

WEDNESDAY | MARCH 25, 2020

8.00 Registration & Morning Refreshments

8.45 Chair's Opening Remarks

Advancing Preclinical Autoimmune Models

David Fox
Professor of
Rheumatology &
Professor of Internal
Medicine
**University of
Michigan**

9.00 New Targets for the Treatment of Autoimmunity – CD6 & CD13

- Ligands of CD6 include both CD166 (ALCAM) and CD318
- Interruption of the interaction between CD6 and CD318 prevents or reverses autoimmune diseases driven by Th1 and/or Th17 cells
- Soluble CD13, shed from the surface of activated fibroblasts, is a powerful chemotactic, angiogenic and inflammation-inducing molecule, that acts through a GPCR
- Inhibitors of CD13 or its receptor have potent anti-inflammatory effects

Hella Kohlhof
Chief Scientific
Officer
Immunix AG

9.30 Mapping the Molecular Profile IMU-935 for the Treatment of Autoimmune Diseases

- Identification of the unique molecular profile of the ROR γ T inverse agonist IMU-935
- Choosing the right animal models to demonstrate ROR γ T impact on disease outcome



10.00 Speed Networking & Morning Refreshments

Your chance to continue the focused discussion with each individual expert as we break out into small interactive groups.

Sunhwa Kim
Principal Scientist
Merck & Co

11.15 Latest Progress Applying Combination Therapeutics Targeting RA & IBD

- Key preclinical considerations to develop combination therapy in autoimmune diseases
- Case studies of RA and IBD: MMP9 antagonist and JAK inhibitor

Roland Grenningloh
Senior Director,
Immunology
Neurology
EMD Serono

11.45 Preclinical Modeling of BTK inhibitors for Autoimmune Diseases

- Comparison of impact of genetic BTK deficiency versus pharmacological inhibition
- Measuring target occupancy
- Efficacy data in preclinical models for SLE, RA and MS
- Key takeaways for translation into the clinic

12.15 Networking Lunch

Validating Biological Pathways through Novel Models

Marije Koenders
Assistant Professor
**Radboud Institute
for Molecular Life
Sciences (RIMLS)**

13.15 Effector vs. Regulatory T Cell Disbalance During Chronic Inflammation

- Targeting the IL-17/Th17 pathway is challenging due to Th17 plasticity, CD4+ T cell polyfunctionality and cytokine synergy
- The microbiome is an important driver of Th17-dependence
- Innovative translational models to study human synovial pathology are the future

Josef Buttigieg
Associate Professor
University of Regina

13.45 Targeted Approach to Treating Multiple Sclerosis Using Microbiology & Immunology

- Challenges in understanding the pathophysiology of multiple sclerosis
- Current treatment methodologies target symptoms or suppress the entire immune system
- Applying microbiology to devise a targeted approach to eliminating autoimmune cells
- Preliminary studies indicate it is specific with a few interesting twists

14.15 Panel Discussion: Targeting the Innate Immune System

- Understanding the interplay between how macrophages and monocytes drive pathogenic disease progression
- Outlining the relevant strategies of disease treatment across RA, SLE, MS and T1D
- The need to elucidate a more detailed and comprehensive mechanism of macrophage/monocyte regulation in autoimmune diseases
- How can variables, e.g. sex, age, genetics and environmental factors, be modeled to drive more effective therapeutics in specific to the heterogenous population?



Roland Grenningloh
Senior Director -
Immunology Neurology
EMD Serono



Josef Buttigieg
Associate Professor
University of Regina



Sunhwa Kim
Principal Scientist
Merck & Co

15.00 Moderator Feedback

15.15 A Novel Biologics Platform for Antigen-Specific Immunotherapy

Anish Suri
Chief Scientific
Officer
Cue Biopharma

- Insight behind how the ImmunoSTAT platform incorporates pHLA and relevant immune-modulatory signals to directly engage T cells in a patient's body
- Incorporating different HLA alleles, T cell epitopes and secondary signals, which allows for targeting different diseases and patient subsets
- Case study evidence to support selective and specific biological effects on antigen-specific T cells



15.45 Afternoon Networking Break & Poster Session

Alexis Scherl
Scientist, Research
Pathology
Genentech

16.15 Investigating the Potential of α E Integrin in IBD

- The benefits of a novel photoconvertible model to study lymphocyte trafficking in vivo
- The potential implications of α E biology in human IBD

16.45 Roundtable Discussion

Bioinformatics, Metabolomics & Applying New Platforms

- Discuss the future of novel precision therapeutics and companion diagnostics for autoimmune disease patients.
- What are the latest advancing techniques to help uncover a deeper understanding of mechanistic drivers of autoimmune disease?

Autoantibodies as a Biomarker for Early Disease Prognosis

- What techniques are available to explore the underlying mechanisms that drive specific symptoms of disease development?
- Discussing how this can improve our understanding of tolerance induction and disease pathogenesis

Leveraging Population Studies of Rare Genetic Diseases

- What have we gained from the studying well-defined genetic changes in rare disease?
- What advantage can academics and industry gain from a deeper understanding of functional genomics?
- How do clinical patient samples help understand the key gateways in the inflammatory pathway?

Microbiome - Insight Behind the Pathology

- Discussing how intestinal flora influences the outcomes in systemic lupus
- How do gut commensal and periodontal disease help our understanding of the pathology of RA?
- How can this evidence be incorporated into drug development to improve the translational value of *in vivo* models?

17.30 Moderator Feedback

17.45 Chair's Closing Remarks & Poster Session

It was very informative and useful to know the trends in immunotherapy

Padmini Jayaraman, Laboratory Director, Baylor College of Medicine, Past PREDiCT Attendee

CONFERENCE DAY TWO

THURSDAY | MARCH 26, 2020

8.00 Morning Coffee

8.50 Chair's Opening Remarks

Cell Types vs. Model – How to Characterize & Select Your Model Strategy?

Jason DeVoss
Principal Scientist
Amgen Inc.

9.00 Identification & Characterization of a Novel Human-Relevant Gene Associated with Systemic Lupus Erythematosus

- Insight into the translational significance of loci specific genome targeting in systemic lupus erythematosus
- Showcasing the potential for improving validation of in vivo autoimmune disease models

Changyun Hu
Senior Scientist
Jounce Therapeutics

9.30 B Cells in Autoimmune Diabetes: Good, Bad & In-Between

- Showcasing the role of B cells in autoimmune diabetes
- Sharing B cell-mediated immunotherapies for autoimmune diabetes
- Insight on B cell therapy for autoimmune diseases

10.00 Panel Discussion: What Is Open Targets Initiative?

- The latest progress in applying bioinformatics and functional genomics to uncover the specific drivers of autoimmune disease
- Discuss how the targeting memory CD4+ T cells improve our understanding in the development of accurate in vivo models?



Siddharth Sukumaran
Senior Scientist
Genentech



Jason DeVoss
Principal Scientist
Amgen Inc.



Changyun Hu
Senior Scientist
Jounce Therapeutics

10.30 Morning Refreshments

Stephen Miller
Professor -
Microbiology-
Immunology,
Northwestern University

11.00 Successful Translation of a Tolerogenic Therapy for Celiac Disease Using Gliadin-Encapsulating PLG Nanoparticles

- Tolerance induction using antigen-encapsulating PLG nanoparticles (Ag-PLG) recapitulates how self-tolerance is induced and maintained in the hematopoietic system
- Evidence from phase 2 double-blind, placebo-controlled trial in celiac disease patients significantly reducing the gliadin-specific T cell response and preventing intestinal damage upon gluten challenge
- Future disease indications under clinical development include multiple sclerosis (MS), neuromyelitis optica (NMO), and peanut allergy

Petr Ilyinskii
Senior Director
Selecta Biosciences

11.30 Modeling Antigen-specific Immune Tolerance Therapies

- Insight into utilising tolerogenic ImmTOR nanoparticles to address a key challenge in gene therapy, which is vector re-dosing limitations due to adaptive immune responses against the AAV capsid
- The next steps in advancing clinical drug development from preclinical studies

Siddharth Sukumaran
Senior Scientist
Genentech

12.00 The Effective Role of Targeting IL-22

- Interleukin (IL)-22 plays protective roles in infections and in inflammatory diseases.
- UTTR1147A is a recombinant fusion protein that links the human cytokine IL-22 with IgG4 Fc for extended half-life.
- Insight into preclinical in vitro and in vivo studies demonstrating pharmacological activity and support potential regenerative and protective mechanisms in epithelial tissues.

12.30 Networking Lunch

Improving Therapeutic Potential & Pipeline Progression through Autoimmune Models

Michael Mingueneau
Associate Director,
Multiple Sclerosis &
NeuroInflammation
Research
Biogen

13.30 Towards Selective Immunomodulation of Microglia: Are Fc Receptors (FcRs) for Immunoglobulins Attractive Candidate Targets

- Effectively and selectively blocking microglia pathogenic contributions in disease state is a very attractive therapeutic opportunity for neurodegenerative and neuroinflammatory diseases
- Outlining the role of Fc-receptors (FcRs) in the CNS and microglia in developing neurological disease pathology
- Utilizing a novel preclinical model, to support the first evidence for FcR-dependent functions in microglia and how autoantibodies and FcR-signaling modulate microglia physiology in the CNS

Jessica Kenison-White
Senior Scientist
AnTolRx Inc

14.00 The Benefits of Nanoformulation-based Therapies to promote antigen-specific immune tolerance

- Utilizing the aryl hydrocarbon receptor as a novel target to induce FoxP3+ and IL10+ regulatory T cells
- Selectively targeting pathogenic T cells through the delivery of both a self-antigen and an endogenous tolerogenic molecule to induce an anti-inflammatory phenotype
- Therapeutic benefits towards improving translational outcomes in rheumatoid arthritis and multiple sclerosis

Zuoming Sun
Professor
City of Hope Medical Center

14.30 Leveraging Molecular Imaging to Understand New Targets for the Treatment of TH17-Mediated Autoimmune Responses

- RORgt-regulated Th17 function updates
- How will understanding RORgt-regulated Th17 benefit the development of RORgt-based therapy for Th17-mediated autoimmunity?

15.00 Chair's Closing Remarks & End of Conference

■ ■ This was a great meeting for networking and exchanging technological troubles with colleagues. I did learn a lot of useful information for my experiments. There was a very nice collaborative spirit! ■ ■

**Elsa Quintana, Associate Director, Revolution Medicines,
Past PREDICT Attendee**

WORKSHOP DAY

TUESDAY | MARCH 24, 2020

Workshop A

14.00 - 17.00

Exploring a Novel Therapeutic Option- Insight Behind Regulation of Pathogenic T Helper Cell 17 Differentiation

Background:

Professor Sun and his team's recent work focuses on previously neglected post-translational regulation of RORgt. They have identified a sumoylation site and a ubiquitination site, and demonstrated their *in vivo* function by generating two strains of mice expressing RORgt with a point mutation that prevents sumoylation or ubiquitination. The both strains of mice are defective in development of Th17-mediated EAE.

Key Takeaways:

- This case study will explore the mechanisms responsible for post-translational regulation of RORgt
- Exploring the role Th17 cells mediate pathological immune responses responsible for autoimmune diseases, including psoriasis and multiple sclerosis
- Insight behind the latest case study of current therapies available that are targeting transcription factor retinoid acid-related orphan receptor γ t (RORgt)
- Utilizing this information to facilitate the development of drugs specifically targeting Th17-dependent autoimmunity

Workshop Leader



Zuoming Sun

Professor

City of Hope Medical Center


■ I found this an extremely enjoyable meeting and appreciated the diversity of approaches used by the different speakers to address their specific needs. There is no one-size-fits-all preclinical model to test human I/O molecules, however between the options on the table there are hopefully one or two good fits ■

Graham Thomas, Principal Scientist, COI Pharmaceuticals, Past PREDICT Attendee

PARTNER WITH US

Our community of autoimmune drug developers are actively seeking partners who are specialized in advanced models, imaging solutions and preclinical studies to help them accelerate development programs.

If you have a leading solution and want to share your expertise in front of industry leaders such as **Amgen, Jounce Therapeutics, Immunic AG, Cue Biopharma** and **Merck** this is your chance to get in touch.




Raise Brand Awareness

Demonstrate your expertise and service by interacting with KOL's from drug development pipelines and drive an increase in market share through unique branding formats.



Meet and Network with Industry Pioneers

Maximize prospective client interaction with speed networking breaks, 1-2-1 meetings, informal networking receptions and more.



Position Yourself as an Industry Expert

Define your position as an industry thought leader at the forefront of the only meeting dedicated to tackling the challenges of drug development and preclinical modeling in autoimmune disease.

■ This was a nice-sized conference with plenty of networking opportunities, interesting talks, and variety of very solid speakers. The Speed Networking session was a fabulous way to break the ice and make new contacts ■

Heather White, Business Development, Ncardia, Past PREDiCT Attendee

GET INVOLVED



Diane McKenna

Commercial Director, PREDiCT Series

T: +1 617 455 4188

E: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK



[www.autoimmune-modeling.com/
take-part/register](http://www.autoimmune-modeling.com/take-part/register)



Tel: +1 617 455 4188



Email: register@hansonwade.com

Get Involved Before December 20 to Save Up to \$700

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.


Contact: register@hansonwade.com

SECURE YOUR PLACE

Pharma & Biotech	Register & Pay by Friday January 17, 2020	Standard Prices
Conference + 1 Workshop	\$2,048 (Save \$500)	\$2,448
Conference Only	\$1,699 (Save \$400)	\$2,099
Workshops (Each)	\$449	

Academic Pricing	Register & Pay by Friday January 17, 2020	Standard Prices
Conference + 1 Workshop	\$1,698 (Save \$400)	\$1,998
Conference Only	\$1,399 (Save \$300)	\$1,699
Workshops (Each)	\$399	

Technical & Commercial Vendor	Register & Pay by Friday January 17, 2020	Standard Prices
Conference + 1 Workshop	\$3,098 (Save \$400)	\$3,398
Conference Only	\$2,699 (Save \$300)	\$2,999



VENUE

Kabuki Hotel

1625 Post St, San Francisco
CA 94115, United States

For further information or assistance, please visit
www.jdvhotels.com/hotels/california/san-francisco/hotel-kabuki

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH